{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Peptide Show","title":"Michael Blyumin: Can you trust compounded GLP-1s?","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/3e81999e\"></iframe>","width":"100%","height":180,"duration":1476,"description":"Are you getting the GLP-1 you were expecting?\n\nThe promise of weight loss can make starting a GLP-1 sound straightforward. Michael Blyumin wants patients to understand what they’re taking, what they can realistically expect, and what happens when they stop.\nA clinical pharmacist at Stanford Health Care, Michael works with patients managing diabetes and other long-term conditions. He has also co-authored research on medication costs and access.\nHe joins Richard Skaife to discuss the business behind compounded GLP-1s, his concerns about untested formulations, and why successful treatment involves more than the number on the scales.\nHe explains:\n\n■ Compounded GLP-1s versus FDA-approved medicines\n■ The costs and incentives behind the market\n■ Muscle loss, protein and resistance training\n■ Weight regain after stopping treatment\n■ What newer dual and triple agonists could offer\nChapters\n\n\n\nFurther reading\n\nFDA: Information on compounded GLP-1 products, dosing errors and unapproved formulations: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss\n\nPubMed Central: Conference abstract examining changes in fat and lean mass in a 140-person STEP 1 substudy. Lean mass includes more than skeletal muscle: Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study\n\nPubMed: The STEP 1 extension, following participants for a year after semaglutide and the trial’s lifestyle intervention ended: Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension\n\nPubMed: Research co-authored by Michael Blyumin examining changes to Medicare prescription coverage and the cost of GLP-1 medicines: Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage\n\n\nFollow Michael Blyumin\n\nLinkedIn: linkedin.com/in/mgblyumin/\n\nFollow Richard Skaife\n\nLinkedIn: linkedin.com/in/richardskaife/\n\nPeptide Show\n\nWebsite: Peptide.Show\nInstagram: @Peptide.Show\nTikTok:...","thumbnail_url":"https://img.transistorcdn.com/QcXtaDr9qe6jHT4c0BxQri4VufvdedcvMTMLmbuyqSA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mZTg2/YmYyODMzN2NhMDNh/NzMzZGUxMzJhNDFj/YjVmMS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}